Trump's remarks came a day before the Fed was set to announce its next decision on interest rates.Politicsread more
In a tweet, Trump said that he and Xi "had a very good telephone conversation," and that "our respective teams will begin talks prior to our meeting."Politicsread more
Democratic Rep. Maxine Waters on Tuesday requested that Facebook pause its development of Libra, an upcoming cryptocurrency that the company plans to release in 2020.Technologyread more
Tensions between China and the U.S. are threatening to slow global trade further, threatening some Asian economies.Asia Economyread more
Tesla loses vice president of HR and head of diversity, Felicia Mayo, one of a few black woman executives to break Silicon Valley's glass ceiling.Technologyread more
Union Pacific CEO Lance Fritz tells Jim Cramer that he is optimistic about trade relations with China, Mexico, Japan, and the EU.Mad Money with Jim Cramerread more
The S&P 500 is closing in on its all-time high, and is likely to sail past it, as long as the Fed promises lower interest rates and the trade war calms down.Market Insiderread more
American Airlines pilots plan to tell lawmakers they are still concerned about fixes to grounded Boeing 737 Max planes.Airlinesread more
President Donald Trump on Tuesday announced that he will not nominate acting Defense Secretary Patrick Shanahan to hold the position in a permanent capacity. Army Secretary...Politicsread more
"I do expect our stock market to be hammered if nothing positive comes of this G-20 meeting ... the most likely outcome is nothing happens," Jim Cramer says.Mad Money with Jim Cramerread more
See which stocks are posting big moves after the bell on June 18.Market Insiderread more
There's a lot less in some people's wallets because of rising drug prices.
Since 2010, spending on prescription medication by members of Blue Cross Blue Shield health insurance plans has increased by 10 percent each year — for a total spike in spending of 73 percent, a new report revealed Wednesday.
The sharp uptick in overall drug spending came even as use of generic drugs, which tend to be less expensive than brand-name prescriptions, rose significantly. Generics currently account for 82 percent of total prescriptions filled, up from 66 percent in 2010.
The group examined medical claims of more than 30 million people with commercial health plans for its report.
The Blue Cross Blue Shield Association said the increase in spending is the result of "a small fraction of emerging, patented drugs and large year-over-year price increases that are more than offsetting" the growth in generic drug use.
"Current trends suggest that this rapid rise in drug trend costs is likely to continue in future years," said Maureen Sullivan, chief strategy and innovation officer for the BCBSA.
The group said that the cost of brand-name drugs with patent protections and no generic alternative has risen at annual rate of 25 percent since 2010, for a cumulative increase in cost of 285 percent.
"The patent-protected drugs now make up 63 percent of total drug spending, up from 29 percent of in 2010, despite the fact that they comprise less than 10 percent of total prescriptions filled," BCBSA said.
All but three of the top 25 single-source drugs in terms of spending in 2015 saw triple-digit percentage spending increases or even higher since 2010, according to the report.
The biggest increase in spending was a 30,230-percent increase on Gilenya, a treatment for multiple sclerosis made by Novartis.
Watch: Health bill likely to pass